Riociguat

Overview Riociguat (Adempas®), developed by Bayer, is a first-in-class oral soluble guanylate cyclase (sGC) stimulator approved in multiple jurisdictions for the management of pulmonary hypertension (PH). It is indicated for two distinct subtypes: chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH), including inoperable cases or as monotherapy/add-on therapy. Its unique mechanism distinguishes it…